Vanguard Global Advisers
APYX icon

Vanguard Global Advisers’s Apyx Medical APYX Stock Holding History

Vanguard Global Advisers’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.7K Hold
10,619
– – ﹤0.01% 3086
2026
Q1 		$39.2K Buy
+10,619
New +$39.7K ﹤0.01% 3120

Other funds holding APYX

RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Global Advisers's APYX Position: Q2 2026 in Review

Vanguard Global Advisers held its Apyx Medical (APYX) position steady in Q2 2026 at 10,619 shares worth $47.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3086.

Vanguard Global Advisers first reported a position in APYX in Q1 2026 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold APYX as of Q2 2026.

  • Vanguard Global Advisers held 10,619 shares of Apyx Medical worth $47.7K as of Q2 2026.
  • Vanguard Global Advisers left its Apyx Medical share count unchanged in Q2 2026.
  • Apyx Medical made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3086 holding.
  • Vanguard Global Advisers first reported a position in Apyx Medical in Q1 2026 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.